COX-1 and COX-2 expression in canine cutaneous, oral and ocular melanocytic tumours

Journal of Comparative Pathology

Volumn 143, Issue 2-3, 2010, Pages 142-149

  Pires, I ^a   Garcia, A ^a   Prada, J ^a   Queiroga, F L ^a  

^a UNIVERSITY OF TRÁS OS MONTES AND ALTO DOURO   (Portugal)

Author keywords

COX 1; COX 2; Dog; Malignant melanoma

Indexed keywords

CYCLOOXYGENASE 1; CYCLOOXYGENASE 2;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DOG; EYE TUMOR; MELANOCYTOSIS; MELANOMA; MOUTH TUMOR; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SKIN TUMOR;

ANIMALS; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; CYCLOOXYGENASE INHIBITORS; DOG DISEASES; DOGS; EYE; EYE NEOPLASMS; MELANOCYTES; MELANOMA; MOUTH NEOPLASMS; SKIN; SKIN NEOPLASMS;

CANIS FAMILIARIS;

EID: 77954956802     PISSN: 00219975     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jcpa.2010.01.016     Document Type: Article

References (47)

1. Arber N. Cyclooxygenase-2 inhibitors in colorectal cancer prevention: point. Cancer Epidemiology, Biomarkers and Prevention 2008, 17:1852-1857.
2. Becker M.R., Siegelin M.D., Rompel R., Enk A.H., Gaiser T. COX-2 expression in malignant melanoma: a novel prognostic marker?. Melanoma Research 2009, 19:8-16.
3. Bergman P.J. Canine oral melanoma. Clinical Techniques in Small Animal Practice 2007, 22:55-60.
4. Borzacchiello G., Paciello O., Papparella S. Expression of cyclooxygenase-1 and -2 in canine nasal carcinomas. Journal of Comparative Pathology 2004, 131:70-76.
5. Borzacchiello G., Russo V., Russo M. Immunohistochemical expression of cyclooxygenase-2 in canine ovarian carcinomas. Journal of Veterinary Medicine Series A. Physiology, Pathology and Clinical Medicine 2007, 54:247-249.
6. Chwirot B.W., Kuzbicki L. Cyclooxygenase-2 (COX-2): first immunohistochemical marker distinguishing early cutaneous melanomas from benign melanocytic skin tumours. Melanoma Research 2007, 17:139-145.
7. Cryan L.M., Paraoan L., Hiscott P., Damato B.E., Grierson I., et al. Expression of COX-2 and prognostic outcome in uveal melanoma. Current Eye Research 2008, 33:177-184.
8. Dang C.T., Shapiro C.L., Hudis C.A. Potential role of selective COX-2 inhibitors in cancer management. Oncology (Williston Park) 2002, 16(Suppl. 4):30-36.
9. Denkert C., Kobel M., Berger S., Siegert A., Leclere A., et al. Expression of cyclooxygenase-2 in human malignant melanoma. Cancer Research 2001, 61:303-308.
10. Dias Pereira P., Lopes C.C., Matos A.J., Santos M., Gartner F., et al. COX-2 expression in canine normal and neoplastic mammary gland. Journal of Comparative Pathology 2009, 140:247-253.
11. Dubois R.N., Abramson S.B., Crofford L., Gupta R.A., Simon L.S., et al. Cyclooxygenase in biology and disease. FASEB Journal 1998, 12:1063-1073.
12. Dvory-Sobol H., Arber N. Cyclooxygenase-2 as target for chemopreventive interventions: new approaches. Cancer Biomarkers 2007, 3:153-161.
13. Falandry C., Canney P.A., Freyer G., Dirix L.Y. Role of combination therapy with aromatase and cyclooxygenase-2 inhibitors in patients with metastatic breast cancer. Annals of Oncology 2009, 20:615-620.
14. Figueiredo A., Caissie A.L., Callejo S.A., McLean I.W., Gold P., et al. Cyclooxygenase-2 expression in uveal melanoma: novel classification of mixed-cell-type tumours. Canadian Journal of Ophthalmology 2003, 38:352-356.
15. Frota A.C., Odashiro A.N., Pereira P.R., Fernandes B.F., Godeiro K.D., et al. Immunohistochemical expression of COX-2 and c-kit in metastatic uveal melanoma. Canadian Journal of Ophthalmology 2007, 42:145-146.
16. Goldschmidt M., Dunstan R., Stannard A. Histological Classification of Epithelial and Melanocytic Tumors of the Skin of Domestic Animals 1998, Armed Forces Institute of Pathology, American Registry of Pathology, Washington DC, pp. 38-40.
17. Goulet A.C., Einsphar J.G., Alberts D.S., Beas A., Burk C., et al. Analysis of cyclooxygenase-2 (COX-2) expression during malignant melanoma progression. Cancer Biology and Therapeutics 2003, 2:713-718.
18. Heller D.A., Clifford C.A., Goldschmidt M.H., Holt D.E., Manfredi M.J., et al. Assessment of cyclooxygenase-2 expression in canine hemangiosarcoma, histiocytic sarcoma, and mast cell tumor. Veterinary Pathology 2005, 42:350-353.
19. Hla T., Bishop-Bailey D., Liu C.H., Schaefers H.J., Trifan O.C. Cyclooxygenase-1 and -2 isoenzymes. International Journal of Biochemistry and Cell Biology 1999, 31:551-557.
20. Howe L.R., Subbaramaiah K., Brown A.M., Dannenberg A.J. Cyclooxygenase-2: a target for the prevention and treatment of breast cancer. Endocrine Related Cancer 2001, 8:97-114.
21. Impellizeri J.A., Esplin D.G. Expression of cyclooxygenase-2 in canine nasal carcinomas. Veterinary Journal 2008, 176:408-410.
22. Iwama T. NSAIDs and colorectal cancer prevention. Journal of Gastroenterology 2009, 44(Suppl. 19):72-76.
23. Khan K.N., Knapp D.W., DeNicola D.B., Harris R.K. Expression of cyclooxygenase-2 in transitional cell carcinoma of the urinary bladder in dogs. American Journal of Veterinary Research 2000, 61:478-481.
24. Knottenbelt C., Mellor D., Nixon C., Thompson H., Argyle D.J. Cohort study of COX-1 and COX-2 expression in canine rectal and bladder tumours. Journal of Small Animal Practice 2006, 47:196-200.
25. Kuzbicki L., Sarnecka A., Chwirot B.W. Expression of cyclooxygenase-2 in benign naevi and during human cutaneous melanoma progression. Melanoma Research 2006, 16:29-36.
26. L'Eplattenier H.F., Lai C.L., van den Ham R., Mol J., van Sluijs F., et al. Regulation of COX-2 expression in canine prostate carcinoma: increased COX-2 expression is not related to inflammation. Journal of Veterinary Internal Medicine 2007, 21:776-782.
27. Lanas A., Ferrandez A. NSAIDs and the colon. Current Opinion in Gastroenterology 2009, 25:44-49.
28. McEntee M.F., Cates J.M., Neilsen N. Cyclooxygenase-2 expression in spontaneous intestinal neoplasia of domestic dogs. Veterinary Pathology 2002, 39:428-436.
29. Mohammed S.I., Craig B.A., Mutsaers A.J., Glickman N.W., Snyder P.W., et al. Effects of the cyclooxygenase inhibitor, piroxicam, in combination with chemotherapy on tumor response, apoptosis, and angiogenesis in a canine model of human invasive urinary bladder cancer. Molecular Cancer Therapeutics 2003, 2:183-188.
30. Mohammed S.I., Khan K.N., Sellers R.S., Hayek M.G., DeNicola D.B., et al. Expression of cyclooxygenase-1 and 2 in naturally-occurring canine cancer. Prostaglandins, Leukotrienes and Essential Fatty Acids 2004, 70:479-483.
31. Morita I., Schindler M., Regier M.K., Otto J.C., Hori T., et al. Different intracellular locations for prostaglandin endoperoxide H synthase-1 and -2. Journal of Biological Chemistry 1995, 270:10902-10908.
32. Mullins M.N., Lana S.E., Dernell W.S., Ogilvie G.K., Withrow S.J., et al. Cyclooxygenase-2 expression in canine appendicular osteosarcomas. Journal of Veterinary Internal Medicine 2004, 18:859-865.
33. Nicolaou A., Estdale S.E., Tsatmali M., Herrero D.P., Thody A.J. Prostaglandin production by melanocytic cells and the effect of alpha-melanocyte stimulating hormone. FEBS Letters 2004, 570:223-226.
34. O'Banion M.K., Winn V.D., Young D.A. cDNA cloning and functional activity of a glucocorticoid-regulated inflammatory cyclooxygenase. Proceedings of the National Academy of Sciences USA 1992, 89:4888-4892.
35. Parfenova H., Parfenov V.N., Shlopov B.V., Levine V., Falkos S., et al. Dynamics of nuclear localization sites for COX-2 in vascular endothelial cells. American Journal of Physiology - Cell Physiology 2001, 281:C166-C178.
36. Queiroga F.L., Alves A., Pires I., Lopes C. Expression of Cox-1 and Cox-2 in canine mammary tumours. Journal of Comparative Pathology 2007, 136:177-185.
37. Queiroga F.L., Perez-Alenza M.D., Silvan G., Pena L., Lopes C., et al. Cox-2 levels in canine mammary tumors, including inflammatory mammary carcinoma: clinicopathological features and prognostic significance. Anticancer Research 2005, 25:4269-4275.
38. Raab Y., Sundberg C., Hallgren R., Knutson L., Gerdin B. Mucosal synthesis and release of prostaglandin E2 from activated eosinophils and macrophages in ulcerative colitis. American Journal of Gastroenterology 1995, 90:614-620.
39. Ramos-Vara J.A., Beissenherz M.E., Miller M.A., Johnson G.C., Pace L.W., et al. Retrospective study of 338 canine oral melanomas with clinical, histologic, and immunohistochemical review of 129 cases. Veterinary Pathology 2000, 37:597-608.
40. Reddy B.S., Hirose Y., Lubet R., Steele V., Kelloff G., et al. Chemoprevention of colon cancer by specific cyclooxygenase-2 inhibitor, celecoxib, administered during different stages of carcinogenesis. Cancer Research 2000, 60:293-297.
41. Salmenkivi K., Haglund C., Ristimaki A., Arola J., Heikkila P. Increased expression of cyclooxygenase-2 in malignant pheochromocytomas. Journal of Clinical Endocrinology and Metabolism 2001, 86:5615-5619.
42. Scuderi M.R., Anfuso C.D., Lupo G., Motta C., Romeo L., et al. Expression of Ca(2+)-independent and Ca(2+)-dependent phospholipases A(2) and cyclooxygenases in human melanocytes and malignant melanoma cell lines. Biochimica et Biophysica Acta 2008, 1781:635-642.
43. Shattuck-Brandt R.L., Varilek G.W., Radhika A., Yang F., Washington M.K., et al. Cyclooxygenase-2 expression is increased in the stroma of colon carcinomas from IL-10 (-/-) mice. Gastroenterology 2000, 118:337-345.
44. Smith S.H., Goldschmidt M.H., McManus P.M. A comparative review of melanocytic neoplasms. Veterinary Pathology 2002, 39:651-678.
45. Spangler W.L., Kass P.H. The histologic and epidemiologic bases for prognostic considerations in canine melanocytic neoplasia. Veterinary Pathology 2006, 43:136-149.
46. Sucic M., Boban D., Markovic-Glamocak M., Jakic-Razumovic J., Vrbanec D., et al. Expression of cyclooxygenase-2 in fine-needle aspirates from breast carcinoma and benign breast diseases. Breast 2003, 12:51-57.
47. Williams C.S., DuBois R.N. Prostaglandin endoperoxide synthase: why two isoforms?. American Journal of Physiology 1996, 270:G393-G400.